Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

6 Dec 2010

Abstract excerpt

BACKGROUND: Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia. The expansion of mutant BCR-ABL-positive clones under selective pressure of tyrosine kinase inhibition is referred to as clonal selection; there are few data on the reversibility of this phenomenon. DESIGN AND METHODS: The changes of expression of mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21134983
DOI: 10.3324/haematol.2010.030999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapyPMID 21134983Read ↗

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinibSemantic proximity Read ↗

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABLSemantic proximity Read ↗

Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.Semantic proximity Read ↗

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.Semantic proximity Read ↗

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaSemantic proximity Read ↗

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibSemantic proximity Read ↗

Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.Semantic proximity Read ↗

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.Semantic proximity Read ↗

Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease featuresSemantic proximity Read ↗

BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib TreatmentSemantic proximity Read ↗

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.Semantic proximity Read ↗

Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.